Is Viridian Therapeutics Stock a Good Investment?
Viridian Therapeutics Investment Advice | VRDN |
- Examine Viridian Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Viridian Therapeutics' leadership team and their track record. Good management can help Viridian Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Healthcare space and any emerging trends that could impact Viridian Therapeutics' business and its evolving consumer preferences.
- Compare Viridian Therapeutics' performance and market position to its competitors. Analyze how Viridian Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Viridian Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Viridian Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Viridian Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Viridian Therapeutics is a good investment.
Sell | Buy |
Strong Buy
Market Performance | Solid | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Viridian Therapeutics Stock
Researching Viridian Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 100.0% of the company outstanding shares are owned by institutional investors. The book value of Viridian Therapeutics was at this time reported as 5.09. The company recorded a loss per share of 3.24. Viridian Therapeutics last dividend was issued on the 13th of November 2020. The entity had 1:15 split on the 13th of November 2020.
To determine if Viridian Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Viridian Therapeutics' research are outlined below:
| The company reported the previous year's revenue of 302 K. Net Loss for the year was (269.95 M) with loss before overhead, payroll, taxes, and interest of (237.02 M). | |
| Viridian Therapeutics currently holds about 161.21 M in cash with (232.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.66. | |
| Over 100.0% of the company outstanding shares are owned by institutional investors |
Viridian Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Viridian Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Viridian Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Viridian Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.38 B.Basic technical analysis of Viridian Stock
As of the 5th of August, Viridian Therapeutics has the Semi Deviation of 2.17, coefficient of variation of 488.69, and Risk Adjusted Performance of 0.1714. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Viridian Therapeutics, as well as the relationship between them.Viridian Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Viridian Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Viridian Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Viridian Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Viridian Therapeutics' Outstanding Corporate Bonds
Viridian Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Viridian Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Viridian bonds can be classified according to their maturity, which is the date when Viridian Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Viridian Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Viridian Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1714 | |||
| Market Risk Adjusted Performance | 0.4994 | |||
| Mean Deviation | 2.36 | |||
| Semi Deviation | 2.17 | |||
| Downside Deviation | 2.59 | |||
| Coefficient Of Variation | 488.69 | |||
| Standard Deviation | 2.98 | |||
| Variance | 8.87 | |||
| Information Ratio | 0.1632 | |||
| Jensen Alpha | 0.4607 | |||
| Total Risk Alpha | 0.1789 | |||
| Sortino Ratio | 0.1875 | |||
| Treynor Ratio | 0.4894 | |||
| Maximum Drawdown | 14.7 | |||
| Value At Risk | (3.16) | |||
| Potential Upside | 5.89 | |||
| Downside Variance | 6.72 | |||
| Semi Variance | 4.7 | |||
| Expected Short fall | (2.72) | |||
| Skewness | 0.1636 | |||
| Kurtosis | (0.10) |
| Risk Adjusted Performance | 0.1714 | |||
| Market Risk Adjusted Performance | 0.4994 | |||
| Mean Deviation | 2.36 | |||
| Semi Deviation | 2.17 | |||
| Downside Deviation | 2.59 | |||
| Coefficient Of Variation | 488.69 | |||
| Standard Deviation | 2.98 | |||
| Variance | 8.87 | |||
| Information Ratio | 0.1632 | |||
| Jensen Alpha | 0.4607 | |||
| Total Risk Alpha | 0.1789 | |||
| Sortino Ratio | 0.1875 | |||
| Treynor Ratio | 0.4894 | |||
| Maximum Drawdown | 14.7 | |||
| Value At Risk | (3.16) | |||
| Potential Upside | 5.89 | |||
| Downside Variance | 6.72 | |||
| Semi Variance | 4.7 | |||
| Expected Short fall | (2.72) | |||
| Skewness | 0.1636 | |||
| Kurtosis | (0.10) |
Consider Viridian Therapeutics' intraday indicators
Viridian Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Viridian Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Viridian Therapeutics time-series forecasting models is one of many Viridian Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Viridian Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Viridian Stock media impact
There is far too much social signal, news, headlines, and media speculation about Viridian Therapeutics that are available to investors today. This information is accessible both publicly - through Viridian Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Viridian-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Viridian Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Viridian Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Viridian Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Viridian Therapeutics alpha.
Viridian Therapeutics Corporate Management
| Kyle Haraldsen | Chief Officer | Profile | |
| Melissa Manno | Chief Officer | Profile | |
| MBA MD | Chief Officer | Profile | |
| Jonathan MBA | CEO, CoFounder | Profile | |
| Shan Wu | Chief Officer | Profile | |
| Vahe Bedian | CoFounder Scientist | Profile | |
| Lara Meisner | Sr Counsel | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Healthcare space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Viridian Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.